MedTrace Logo

Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.

NCT04722471 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347

Last updated 2021-03-19

No results posted yet for this study

Summary

This study aims to compare the efficacy, in terms of progesterone levels and clinical outcomes, of two different presentations of micronized vaginal progesterone (400 mg vs. 200 mg) used in endometrial preparation in artificial cycle (AC) for embryo transfer.

This is a non-inferiority, retrospective case-control study, with at least 200 cycles analyzed (at least 100 per arm) and the primary outcome is the serum progesterone level on the day of the embryo transfer.

Conditions

  • Luteal Phase Defect

Interventions

DRUG

Vaginally administered progesterone

The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)

Sponsors & Collaborators

  • Instituto Bernabeu

    lead OTHER

Principal Investigators

  • Joaquín Llácer, MD PhD · Instituto Bernabeu

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2021-03-03
Completion
2021-03-17

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04722471 on ClinicalTrials.gov